HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.
Stocks · News reference
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Ionis and Roche report positive Phase 3 IMAgINATION trial interim results for sefaxersen in treating primary IgA nephropathy.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Ionis Pharmaceuticals announced positive phase III results for two partnered programs: ulefnersen (FUSION study) for FUS-ALS met its primary endpoint with Otsuka planning regulatory discussions, and sefaxersen (IMAgINATION study) for IgAN showed statistically significant proteinuria reductions with Roche continuing the trial. These wins come after recent clinical setbacks in cardiovascular programs but follow FDA approval of Zanvastro for Alexander disease.
8-K filing — IONIS PHARMACEUTICALS INC (IONS)
Filed: 2026-09-23 AccNo: 0001140361-26-037371 Size: 187 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
Merck reports Phase 2b/3 BRUNELLO trial data for remigromig in DME, achieving vision non-inferiority to ranibizumab alongside elevated adverse event rates.
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight
The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.
Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics
Atavistik Bio entered into a strategic research collaboration with Roche to discover and develop novel small molecule therapeutics for cardiovascular, renal, and metabolic diseases using Atavistik's proprietary AMPS platform. Atavistik will receive $70 million upfront with potential milestone payments up to $1.9 billion plus tiered royalties, while Roche will handle preclinical and clinical development, regulatory, and commercialization activities.